Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Wheaton Precious Metals Corp — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Wheaton Precious Metals Corp trades at $132.4 (market cap $61.55B). The key difference: Wheaton Precious Metals Corp is far larger — about 12.6× Travere Therapeutics Inc. Common Stock's market cap, and Wheaton Precious Metals Corp pays a 0.57% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Wheaton Precious Metals Corp for 66 Days on average.
| TVTX | WPM | |
|---|---|---|
Market Cap | $4.88B | $61.55B |
Volume | 1,668,577 | 932,802 |
Sector | Health | Basic Materials |
52-Week High | $67.52 | $165.72 |
52-Week Low | $26.79 | $94.37 |
Typical Hold Time | 0 Days | 66 Days |
Enterprise Value | $5.01B | $63.43B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Wheaton Precious Metals (WPM) trades at $129.58, down 6.18% over 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported record 2025 revenue of $2.31 billion and net income of $1.47 billion, with earnings beating estimates in recent quarters. Management targets 50% production growth by 2030 without new capital, supported by a strong deal pipeline.
WPM presents a growth opportunity with high profitability margins and analyst consensus favoring a buy rating, but faces risks from gold price volatility and execution of expansion plans. The stock's valuation multiples are elevated, requiring sustained earnings growth to justify current levels amid macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
